Comparing MetaVia (MTVA) and Its Competitors

MetaVia (NASDAQ:MTVA) is one of 617 publicly-traded companies in the “MED – BIOMED/GENE” industry, but how does it compare to its competitors? We will compare MetaVia to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Insider and Institutional Ownership

1.4% of MetaVia shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 0.8% of MetaVia shares are held by company insiders. Comparatively, 13.7% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares MetaVia and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-212.00%	-107.21%
MetaVia Competitors	-1,425.99%	-589.65%	-28.81%

Earnings and Valuation

This table compares MetaVia and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
MetaVia	N/A	-$27.59 million	-0.94
MetaVia Competitors	$959.04 million	-$45.27 million	12.93

MetaVia’s competitors have higher revenue, but lower earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

MetaVia has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, MetaVia’s competitors have a beta of 0.97, meaning that their average share price is 3% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for MetaVia and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1	0	2	0	2.33
MetaVia Competitors	5856	12211	37670	1170	2.60

MetaVia presently has a consensus target price of $7.50, indicating a potential upside of 951.30%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.81%. Given MetaVia’s higher possible upside, equities research analysts clearly believe MetaVia is more favorable than its competitors.

Summary

MetaVia competitors beat MetaVia on 8 of the 13 factors compared.

About MetaVia

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.